Retatrutide

Retatrutide is an investigational synthetic peptide developed as a once-weekly injectable candidate. It acts as a triple receptor agonist, simultaneously targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is being researched for its potential to reduce appetite, slow gastric emptying, improve glycemic control, increase energy expenditure, and promote substantial body weight reduction, along with possible benefits on metabolic health, fat mass, and lipid profiles. As of 2026, Retatrutide remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is in late-stage clinical development.